

Klarissa D Jackson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6887892/publications.pdf>

Version: 2024-02-01

17
papers

298
citations

1305906

8
h-index

1181555

14
g-index

17
all docs

17
docs citations

17
times ranked

362
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation. <i>Chemical Research in Toxicology</i> , 2022, 35, 792-806. | 1.7 | 8 |
| 2 | Biotransformation novel advances â€“ 2021 year in review. <i>Drug Metabolism Reviews</i> , 2022, 54, 207-245. | 1.5 | 3 |
| 3 | Case Study 11: Considerations for Enzyme Mapping Experimentsâ€™Interaction Between the Aldehyde Inhibitor Hydralazine and Glutathione. <i>Methods in Molecular Biology</i> , 2021, 2342, 809-823. | 0.4 | 1 |
| 4 | Novel advances in biotransformation and bioactivation research â€“ 2020 year in review. <i>Drug Metabolism Reviews</i> , 2021, 53, 384-433. | 1.5 | 4 |
| 5 | Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. <i>Circulation Research</i> , 2021, 128, 1973-1987. | 2.0 | 10 |
| 6 | Cytochrome P450â€™Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol. <i>Drug Metabolism and Disposition</i> , 2021, 49, 882-891. | 1.7 | 30 |
| 7 | Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib. <i>Drug Metabolism and Disposition</i> , 2021, 49, 233-244. | 1.7 | 9 |
| 8 | Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. <i>Xenobiotica</i> , 2020, 50, 132-145. | 0.5 | 4 |
| 9 | Novel advances in biotransformation and bioactivation researchâ€™2019 year in review. <i>Drug Metabolism Reviews</i> , 2020, 52, 333-365. | 1.5 | 5 |
| 10 | Investigating the CYP450â€™Catalyzed Metabolism of Cannabidiol and Its Implications for Drug Safety. <i>FASEB Journal</i> , 2020, 34, 1-1. | 0.2 | 0 |
| 11 | Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1257-1269. | 1.7 | 19 |
| 12 | Providing a New Aniline Bioisostere through the Photochemical Production of 1-Aminonorbornanes. <i>CheM</i> , 2019, 5, 215-226. | 5.8 | 58 |
| 13 | Interindividual Variation in Sunitinib Metabolism in Primary Human Hepatocytes. <i>FASEB Journal</i> , 2019, 33, 820.5. | 0.2 | 0 |
| 14 | HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase III α and II β . <i>Chemical Research in Toxicology</i> , 2018, 31, 137-144. | 1.7 | 13 |
| 15 | Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib. <i>Chemical Research in Toxicology</i> , 2018, 31, 570-584. | 1.7 | 62 |
| 16 | Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2367. | 1.8 | 36 |
| 17 | Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1584-1597. | 1.7 | 36 |